FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate

World Journal of Surgical Oncology

Volumn 6, Issue , 2008, Pages

  Liu, Yiyan ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TOPOTECAN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HEMATURIA; HUMAN; HYDRONEPHROSIS; IMMUNOPATHOLOGY; INTERMETHOD COMPARISON; KIDNEY FAILURE; LIVER METASTASIS; LUNG METASTASIS; LUNG NODULE; LYMPH NODE METASTASIS; MALE; NEPHROSTOMY; NEUROENDOCRINE TUMOR; PREOPERATIVE EVALUATION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; TUMOR DIFFERENTIATION; WHOLE BODY CT; WHOLE BODY PET; METASTASIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

AGED; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 46649117348     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-6-64     Document Type: Article

References (12)

1. Powles T Murray I Brock C Molecular position emission tomography and PET/ CT imaging in urological malignancies Eur Urol 2007, 51:1511-1521. 10.1016/j.eururo.2007.01.061 17275167
2. Effert PJ Bares R Handt S Metabolic imaging of untreated prostate cancer by positron emission tomography with 18F-FDG J Urol 1996, 155:994-998. 10.1016/S0022-5347(01)66366-3 8583625
3. Hofer C Laubenbacher C Block T FDG-PET is useless for the detection of local recurrence after radical prostatectomy Eur Urol 1999, 36:31-35. 10.1159/000019923 10364652
4. Slovin S Neuroendocrine differentiation in prostate cancer: A sheep in wolf's clothing? Nat Clin Pract Urol 2006, 3:138-144. 10.1038/ncpuro0435 16528286
5. Huang J Yao JL di Sant'Agnese PA Immunohistochemical characterization of neuroendocrine cells in prostate cancer Prostate 2006, 66:1399-1406. 10.1002/pros.20434 16865726
6. Pouessel D Gallet B Bibeau F Liver metastases in prostate caicinoma: clinical characteristic and outcome BJU Int 2007, 99:807-811. 10.1111/ j.1464-410X.2006.06663.x 17155968
7. Liu IJ Zafar MB Lai YH Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer Urology 2001, 57:108-115. 10.1016/S0090-4295(00)00896-7 11164153
8. Oyama N Akino H Suzuki Y FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation Nucl Med Commun 2001, 22:963-968. 10.1097/00006231-200109000-00004 11505204
9. Schoder H Herrmann K Gonen M 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy Clin Cancer Res 2005, 11:4761-4769. 10.1158/1078-0432.CCR-05-0249 16000572
10. Morris MJ Akhurst T Larson SM Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy Clin Cancer Res 2005, 11:3210-3216. 2040333 15867215 10.1158/1078-0432.CCR-04-2034
11. Hansson J Abrahamsson PA Neuroendocrine differentiation in prostate carcinoma Scand J Urol Nephrol 2003, 212:28-36. 10.1080/03008880310006922
12. Sundin A PET in the diagnosis of neuroendocrine tumors Ann NY Acad Sci 2004, 1014:246-257. 10.1196/annals.1294.027 15153441